EUVIMEDEUVIMED entdecken
Crossref

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma

Amar H Kelkar iD, Edward R Scheffer Cliff iD, Caron A Jacobson, Gregory A Abel, Stijntje W Dijk iD, Eline M Krijkamp iD, Robert Redd iD, Joanna C Zurko, Mehdi Hamadani, M G Myriam Hunink iD, Corey Cutler iD

Annals of Internal Medicine · 2023-12 · 176 (12) · 1625-1637

DOI: 10.7326/m22-2276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2023-12. Verfasst von Amar H Kelkar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; and Harvard T.H. Chan School of Public Health, …. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 73 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenHematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseHumansCost-Effectiveness AnalysisTransplantation, Autologous

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; and Harvard T.H. Chan School of Public Health, Boston, Massachusetts (A.H.K.).
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Harvard T.H. Chan School of Public Health, Boston; and Program on Regulation, Therapeutics and Law, Brigham and Women…
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, and Harvard Medical School, Boston, Massachusetts (C.A.J., G.A.A., C.C.).
  • Department of Radiology and Nuclear Medicine and Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, the Netherlands (S.W.D.).
  • Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, and Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands (E.M.K.).
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts (R.R.).

ORCID-Profile: Amar H Kelkar, Edward R Scheffer Cliff, Stijntje W Dijk, Eline M Krijkamp, Robert Redd, M G Myriam Hunink, Corey Cutler

Zitieren

APA

Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., & Cutler, C. (2023). Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma. Annals of Internal Medicine, 176(12), 1625-1637. https://doi.org/10.7326/m22-2276

Vancouver

Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, et al. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma. Annals of Internal Medicine. 2023;176(12):1625-1637. doi:10.7326/m22-2276

BibTeX
@article{Kelkar2023,
  author = {Kelkar, Amar H and Cliff, Edward R Scheffer and Jacobson, Caron A and Abel, Gregory A and Dijk, Stijntje W and Krijkamp, Eline M and Redd, Robert and Zurko, Joanna C and Hamadani, Mehdi and Hunink, M G Myriam and Cutler, Corey},
  title = {Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma},
  journal = {Annals of Internal Medicine},
  year = {2023},
  volume = {176},
  number = {12},
  pages = {1625--1637},
  doi = {10.7326/m22-2276}
}
Kostenlos starten →